New compound HPH-15 offers promising alternative to diabetes medications

Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap in diabetes treatment innovation.

Type 2 diabetes, a condition affecting millions worldwide, is often accompanied by complications like fatty liver and insulin resistance, which challenge current treatment methods. The research team, led by Visiting Associate Professor Hiroshi Tateishi and Professor Eiichi Araki, has identified HPH-15 as a promising alternative to existing medications like metformin.

The study, published in Diabetologia, a top journal in the field of diabetes, demonstrates that HPH-15 outperforms metformin by activating AMP-activated protein kinase (AMPK)-;a critical protein regulating energy balance-;at lower doses. HPH-15 not only improved glucose uptake in liver, muscle, and fat cells but also significantly reduced fat accumulation in high-fat diet (HFD)-induced obese mice. Unlike metformin, HPH-15 exhibited additional antifibrotic properties, potentially addressing liver fibrosis and other complications often seen in diabetes patients.

Key findings include:

  • Enhanced efficacy: HPH-15 activated AMPK and promoted glucose uptake at concentrations 200 times lower than metformin.
  • Fat reduction: The compound decreased subcutaneous fat by 44% and mitigated fatty liver more effectively than metformin in preclinical trials.
  • Safety profile: Lactic acid production, a concern with metformin, was either comparable or lower with HPH-15, suggesting reduced risks of lactic acidosis.

These results suggest that HPH-15 could redefine diabetes management by combining glucose control with the prevention of obesity-related complications.

This compound holds transformative potential for diabetes treatment, offering benefits beyond blood sugar regulation."

Professor Mikako Fujita, Faculty of Life Sciences, Kumamoto University

Supported by Japan's AMED Translational Research Program and other initiatives, this breakthrough showcases the innovative strides Kumamoto University is making in addressing global health challenges.

Source:
Journal reference:

Toma, T., et al. (2024) An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models. Diabetologia. doi.org/10.1007/s00125-024-06260-y.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers